Cellosaurus logo
expasy logo

Cellosaurus BC-3 (CVCL_1080)

[Text version]
Cell line name BC-3
Synonyms BC3
Accession CVCL_1080
Resource Identification Initiative To cite this cell line use: BC-3 (RRID:CVCL_1080)
Comments Group: Patented cell line.
Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: LL-100 blood cancer cell line panel.
Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-2277.
Population: Caucasian.
Doubling time: ~50-60 hours (DSMZ=ACC-679).
Microsatellite instability: Stable (MSS) (Sanger).
Transformant: NCBI_TaxID; 37296; Human herpesvirus 8 (HHV-8/KSHV).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
Sequence variations
  • Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19608668).
HLA typing Source: DSMZCellDive=ACC-679
Class I
HLA-AA*02:05:01,03:01:01
HLA-BB*14:02:01,50:01:01
HLA-CC*06:02:01,08:02:01
Class II
HLA-DPDPA1*01:03:01,01:03:01
DPB1*04:01:01,104:01
HLA-DQDQA1*02:01:01,01:01:02
DQB1*02:02:01,05:01:01
HLA-DRDRA*01:01:01,01:01:01
DRB1*01:02:01,07:01:01
Genome ancestry Source: PubMed=30894373

Origin% genome
African7.13
Native American1.02
East Asian, North6.58
East Asian, South0
South Asian6.31
European, North25.3
European, South53.67
Disease Primary effusion lymphoma (NCIt: C6915)
Primary effusion lymphoma (ORDO: Orphanet_48686)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Originate from same individual CVCL_4J72 ! KS-1 [Human primary effusion lymphoma]
Sex of cell Male
Age at sampling 85Y
Category Cancer cell line
STR profile Source(s): ATCC; Cosmic-CLP; DSMZ

Markers:
AmelogeninX
CSF1PO11,12
D2S133824,25
D3S135815,17
D5S81811,12
D7S82010,12
D8S117914,16
D13S31711
D16S53912
D18S5114,21.2
D19S43314,15
D21S1129,30
FGA18,22
Penta D8,13
Penta E7,15
TH016,9
TPOX8,11
vWA14,18

Run an STR similarity search on this cell line
Web pages https://cornell.flintbox.com/technologies/d21d6b39-b480-4ad4-8785-cc7a70c91788
Publications

PubMed=8839859; DOI=10.1182/blood.V88.7.2648.bloodjournal8872648
Arvanitakis L., Mesri E.A., Nador R.G., Said J.W., Asch A.S., Knowles D.M., Cesarman E.
Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus.
Blood 88:2648-2654(1996)

PubMed=9766492; DOI=10.1038/sj.leu.2401160
Drexler H.G., Uphoff C.C., Gaidano G., Carbone A.
Lymphoma cell lines: in vitro models for the study of HHV-8+ primary effusion lymphomas (body cavity-based lymphomas).
Leukemia 12:1507-1517(1998)

Patent=US5908773
Cesarman E., Arvanitakis L., Knowles D.M., Mesri E.A.
KSHV positive cell lines.
Patent number US5908773, 01-Jun-1999

DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)

PubMed=15613351; DOI=10.1128/JVI.79.2.1244-1251.2005
Fan W., Bubman D., Chadburn A., Harrington W.J. Jr., Cesarman E., Knowles D.M.
Distinct subsets of primary effusion lymphoma can be identified based on their cellular gene expression profile and viral association.
J. Virol. 79:1244-1251(2005)

PubMed=17121789; DOI=10.1128/JVI.01757-06
Burd C.E., Sin S.-H., Dittmer D.P.
Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus lymphomas: implications for therapy.
J. Virol. 81:1912-1922(2007)

PubMed=19608668; DOI=10.3324/haematol.2009.007260
Boulanger E., Marchio A., Hong S.-S., Pineau P.
Mutational analysis of TP53, PTEN, PIK3CA and CTNNB1/beta-catenin genes in human herpesvirus 8-associated primary effusion lymphoma.
Haematologica 94:1170-1174(2009)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=21685375; DOI=10.1182/blood-2010-12-323659
Roy D., Sin S.-H., Damania B., Dittmer D.P.
Tumor suppressor genes FHIT and WWOX are deleted in primary effusion lymphoma (PEL) cell lines.
Blood 118:E32-E39(2011)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x
Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.
The LL-100 panel: 100 cell lines for blood cancer studies.
Sci. Rep. 9:8218-8218(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) ATCC; CRL-2277
CCTCC; GDC0221
DSMZ; ACC-679
Cell line databases/resources CLO; CLO_0001891
cancercelllines; CVCL_1080
CCRID; 3101HUMSCSP5016
Cell_Model_Passport; SIDM00895
Cosmic-CLP; 910918
DepMap; ACH-002215
DSMZCellDive; ACC-679
IGRhCellID; BC3
LINCS_LDP; LCL-1948
Anatomy/cell type resources BTO; BTO:0002722
Biological sample resources BioSample; SAMN03472835
BioSamples; SAMEA365848
BioSamples; SAMEA365859
CRISP screens repositories BioGRID_ORCS_Cell_line; 1098
Chemistry resources ChEMBL-Cells; CHEMBL3308890
ChEMBL-Targets; CHEMBL2366371
GDSC; 910918
PharmacoDB; BC3_79_2019
PubChem_Cell_line; CVCL_1080
Encyclopedic resources Wikidata; Q54795189
Experimental variables resources EFO; EFO_0002046
Gene expression databases ArrayExpress; E-MTAB-38
ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-7721
ArrayExpress; E-MTAB-7722
GEO; GSM33135
GEO; GSM38796
GEO; GSM38797
GEO; GSM634733
GEO; GSM710419
GEO; GSM710435
GEO; GSM1669611
GEO; GSM3150237
Polymorphism and mutation databases Cosmic; 687836
Cosmic; 910918
Cosmic; 1238077
Cosmic; 1515188
Cosmic; 1588558
IARC_TP53; 21190
IARC_TP53; 26979
Progenetix; CVCL_1080
Proteomic databases PRIDE; PXD012087
PRIDE; PXD030304
Entry history
Entry creation04-Apr-2012
Last entry update30-Jan-2024
Version number38